Peptech's six-month profits soar to $133M
Australian drugmaker Peptech has reported a record profit of A$137.7 million ($133.1 million) for the half year ending March 31, 2007, one of the largest profits made by an Australian-listed biotechnology company to date.
The firm's healthy results announcement follows on from its A$156.0 million acquisition of fellow Australia-based EvoGenix, a protein therapeutics company earlier this month (Marketletter May 8). Peptech noted that the merged company is poised to become a high profile player in the worldwide antibody and protein therapeutics sector.
During the period, the firm's revenue reached A$17.8 million, up 26% on the like, year-ago period. Peptech's A$137.7 million profit represents a massive 2,145% increase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze